Biomarkers of drugs targeting HER-family signalling in cancer-Reference-Cited by-同舟云学术

Biomarkers of drugs targeting HER-family signalling in cancer

Published:2013-12-10 Issue:2 Volume:232 Page:219-229
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Montemurro Filippo¹,Scaltriti Maurizio²

Affiliation:

1. Unit of Investigative Clinical Oncology (INCO) and Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia; Institute of Candiolo (IRCCs); Str Provinciale 142 10060 Candiolo Italy

2. Human Oncology & Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center; 1275 York Avenue, Box 20 New York NY 10065 USA

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.4269/fullpdf

Reference127 articles.

1. Receptor tyrosine kinase signalling as a target for cancer intervention strategies;Zwick;Endocr Relat Cancer,2001

2. Signal transduction by receptors with tyrosine kinase activity;Ullrich;Cell,1990

3. Binding specificities and affinities of egf domains for ErbB receptors;Jones;FEBS Lett,1999

4. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity;Kochupurakkal;J Biol Chem,2005

5. EGF-ERBB signalling: towards the systems level;Citri;Nature Rev Mol Cell Biol,2006

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer;Drug Design, Development and Therapy;2021-06

2. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention;Current Oncology Reports;2021-05-03

3. Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer;Critical Reviews in Oncology/Hematology;2020-05

4. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers;Cancer Discovery;2020-03-25

5. A new player in the treatment of HER2-positive tumours;The Lancet Oncology;2019-06